JP2020502137A5 - - Google Patents

Download PDF

Info

Publication number
JP2020502137A5
JP2020502137A5 JP2019531817A JP2019531817A JP2020502137A5 JP 2020502137 A5 JP2020502137 A5 JP 2020502137A5 JP 2019531817 A JP2019531817 A JP 2019531817A JP 2019531817 A JP2019531817 A JP 2019531817A JP 2020502137 A5 JP2020502137 A5 JP 2020502137A5
Authority
JP
Japan
Prior art keywords
tremor
syndrome
pharmaceutical composition
formula
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019531817A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502137A (ja
JP7086076B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/KR2017/014743 external-priority patent/WO2018111009A1/ko
Publication of JP2020502137A publication Critical patent/JP2020502137A/ja
Publication of JP2020502137A5 publication Critical patent/JP2020502137A5/ja
Application granted granted Critical
Publication of JP7086076B2 publication Critical patent/JP7086076B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019531817A 2016-12-14 2017-12-14 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用 Active JP7086076B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170225 2016-12-14
KR10-2016-0170225 2016-12-14
PCT/KR2017/014743 WO2018111009A1 (ko) 2016-12-14 2017-12-14 진전 또는 진전 증후군의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2020502137A JP2020502137A (ja) 2020-01-23
JP2020502137A5 true JP2020502137A5 (https=) 2021-01-14
JP7086076B2 JP7086076B2 (ja) 2022-06-17

Family

ID=62558966

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531817A Active JP7086076B2 (ja) 2016-12-14 2017-12-14 振戦又は振戦症候群の予防、軽減又は治療のためのカルバメート化合物の使用

Country Status (13)

Country Link
US (1) US11033531B2 (https=)
EP (1) EP3556364B1 (https=)
JP (1) JP7086076B2 (https=)
KR (1) KR102635941B1 (https=)
CN (1) CN110267657B (https=)
AU (1) AU2017374459B2 (https=)
CL (1) CL2019001623A1 (https=)
ES (1) ES3039979T3 (https=)
IL (1) IL267191B2 (https=)
MX (1) MX391363B (https=)
MY (1) MY198417A (https=)
WO (1) WO2018111009A1 (https=)
ZA (1) ZA201903749B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3711760B1 (en) * 2017-11-14 2024-02-14 SK Biopharmaceuticals Co., Ltd. Use of carbamate compound for preventing or treating diseases associated with increase in late sodium current
ES2978226T3 (es) * 2018-09-21 2024-09-09 Sk Biopharmaceuticals Co Ltd Compuesto de carbamato y uso de la formulación que lo comprende para prevenir, aliviar o tratar el trastorno de estrés agudo o el trastorno de estrés postraumático

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1411917E (pt) 2001-02-27 2007-09-17 Ortho Mcneil Pharm Inc ''compostos carbamatos para utilização na prevenção ou tratamento de distúrbios do movimento''
CN1938031A (zh) * 2004-03-29 2007-03-28 默克公司 作为钠通道阻滞剂的联芳取代的吡嗪酮类
US7598279B2 (en) * 2005-04-22 2009-10-06 Sk Holdings Co., Ltd. Neurotherapeutic azole compounds
WO2008107909A1 (en) * 2007-03-05 2008-09-12 Indus Biotech Private Limited Pharmaceutical compositions comprising trigonelline and 4-hydroxyisoleucine and a process thereof
WO2010150946A1 (en) 2009-06-22 2010-12-29 Sk Holdings Co., Ltd. Method for preparation of carbamic acid (r)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
CN109939092B (zh) 2013-03-12 2022-03-22 比皮艾思药物研发有限公司 用于预防或治疗小儿癫痫和癫痫相关综合征的苯基氨基甲酸酯化合物
KR102489052B1 (ko) 2016-05-19 2023-01-16 에스케이바이오팜 주식회사 섬유근육통 또는 섬유근육통의 연관된 기능적 증후군을 예방 또는 치료하기 위한 카바메이트 화합물의 용도

Similar Documents

Publication Publication Date Title
JP2016512531A5 (https=)
RU2015143610A (ru) Лечение катаплексии
JP2012530779A5 (https=)
JP2011505347A5 (https=)
RU2012101947A (ru) Способы лечения и профилактики усталости
JP2019524883A5 (https=)
JP2019519598A5 (https=)
JP2015532295A5 (https=)
JP2019516739A5 (https=)
JP2003509349A5 (https=)
RU2019141734A (ru) Терапевтические соединения и композиции и способы их применения
JP2006503850A5 (https=)
JP2019516707A5 (https=)
RU2011147186A (ru) 2, 5-дизамещенные арилсульфонамидные антагонисты ссr3
JP2019520344A5 (https=)
JP2011518168A5 (https=)
CA2555457A1 (en) A novel therapeutic agent for amyotrophic lateral sclerosis (als) or diseases caused by als
JP2010506919A5 (https=)
JP2007502832A5 (https=)
JP2020502137A5 (https=)
RU2017134285A (ru) Борсодержащие низкомолекулярные соединения как антипротозойные агенты
JP2019516726A5 (https=)
JP2016537432A5 (https=)
JP2020502106A5 (https=)
JP2008521934A5 (https=)